Form D · Biotechnology
Pana Bio, Inc.
Houston, TX · CIK 0001876619
Offering snapshot reported Nov 3, 2021 · SEC filing
- Reported sold
- $200K Offering amount: $2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 19, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 3, 2021 | Initial | $200,000 | No comparison | 1 | SEC filing |
| Aug 3, 2021 | Initial | $60,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-419609
Source: Form D, filed Nov 3, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Britton | Director |
| Jinglin Huang | Executive |
| Jeffrey Tabor | Director |
| Omid Veiseh | Director |
| David Yu Zhang | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
6711 Stella Link Road Mailbox #563
Houston, TX, 77005
Houston, TX, 77005